Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol vs labetalol in cataract surgery for patients with chronic hypertension
IRCT20221108056442N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hypertension (HTN) and cardiac ischemia comparing Esmolol arm with Labetalol arm (2 arms). Primary endpoints: Incidence of cardiovascular complications during cataract surgery and Intraoperative ischemic changes. Started Dec 2022; status: completed.
02
Drugs
esmolollabetalol
03
Conditions
hypertension (HTN)cardiac ischemia
Beyond the preview
Go deeper on IRCT20221108056442N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221108056442N1.